It’s an excellent interview to watch. DW again points out that it’s the surgeons who are leading the way with new opportunities for using the Novosorb tech, and not just BTM. But I do like his focus on at present going all out for the “low hanging fruit” of BTM use in the US.
As for the shorters, they are his “friends” because at some point they are going to have to cover approx 60 million shares. I get the feeling that he thinks that this might occur before PNV drops from the index. But if it doesn’t the business will still continue to make progress and eventually the game will have been played out.
PNV Price at posting:
$1.05 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)